P16 The combined type-I interferon and neutrophil gene scores identify highly active systemic lupus erythematosus patients and performed better than classical serological markers. (23rd March 2020)
- Record Type:
- Journal Article
- Title:
- P16 The combined type-I interferon and neutrophil gene scores identify highly active systemic lupus erythematosus patients and performed better than classical serological markers. (23rd March 2020)
- Main Title:
- P16 The combined type-I interferon and neutrophil gene scores identify highly active systemic lupus erythematosus patients and performed better than classical serological markers
- Authors:
- Chasset, François
Ribi, Camillo
Trendelenburg, Marten
Huynh-Do, Uyen
Roux-Lombard, Pascale
Courvoisier, Delphine S
Chizzolini, Carlo - Abstract:
- Abstract : Background: In SLE, heterogeneous clinical expression and activity may reflect diverse pathogenic and/or effector mechanisms. We dwelled into SLE heterogeneity by assessing the expression of three gene sets representative of type I interferon (IFN-I), neutrophil-(PMN) and plasmablast-(PB) signatures in a well characterized, multidisciplinary cohort of SLE patients. We further assessed whether individual gene products could be representative of these three signatures. Methods: Whole blood, serum and clinical data were obtained from 140 SLE individuals. Gene expression was assessed by NanoString© technology, using a panel of 37 probes allowing the computation of six IFN-I, one PMN and one PB scores. Protein levels were measured by ELISA. Results: High IFN-I gene expression was found in 45 to 50% of SLE individuals, depending on the score used. All 6 IFN-I scores were significantly associated with active skin involvement and 2 of 6 with arthritis. Interferon-induced GTP-binding protein Mx1 (MX1) correlated with IFN-I score (p<0.0001) and was associated with a similar clinical phenotype. High PMN gene expression was found in 25% of individuals in association with SLE fever, serositis, leukopenia and glucocorticoid use. PB gene expression was highly influenced by immunosuppressant agents with no association with SLE features. The combined IFN-I and PMN gene expression was significantly associated with high disease activity and outperformed anti-dsDNA, anti C1q andAbstract : Background: In SLE, heterogeneous clinical expression and activity may reflect diverse pathogenic and/or effector mechanisms. We dwelled into SLE heterogeneity by assessing the expression of three gene sets representative of type I interferon (IFN-I), neutrophil-(PMN) and plasmablast-(PB) signatures in a well characterized, multidisciplinary cohort of SLE patients. We further assessed whether individual gene products could be representative of these three signatures. Methods: Whole blood, serum and clinical data were obtained from 140 SLE individuals. Gene expression was assessed by NanoString© technology, using a panel of 37 probes allowing the computation of six IFN-I, one PMN and one PB scores. Protein levels were measured by ELISA. Results: High IFN-I gene expression was found in 45 to 50% of SLE individuals, depending on the score used. All 6 IFN-I scores were significantly associated with active skin involvement and 2 of 6 with arthritis. Interferon-induced GTP-binding protein Mx1 (MX1) correlated with IFN-I score (p<0.0001) and was associated with a similar clinical phenotype. High PMN gene expression was found in 25% of individuals in association with SLE fever, serositis, leukopenia and glucocorticoid use. PB gene expression was highly influenced by immunosuppressant agents with no association with SLE features. The combined IFN-I and PMN gene expression was significantly associated with high disease activity and outperformed anti-dsDNA, anti C1q and complement levels to predict SLE activity. Conclusions: The IFN-I and PMN gene scores segregate with distinct SLE clinical features and their joint expression identify high disease activity. MX1 protein levels perform similarly to IFN-I gene expression. Acknowledgements: Work partially supported by funds provided by a grant from Fondation Fleurette Wagemakers, Sion (Switzerland), by a grant from La Société Académique de Genève (Switzerland). FC was supported by a research travel grant from the French Society of Dermatology and from Institut Servier, Paris (France). … (more)
- Is Part Of:
- Lupus science & medicine. Volume 7(2020)Supplement 1
- Journal:
- Lupus science & medicine
- Issue:
- Volume 7(2020)Supplement 1
- Issue Display:
- Volume 7, Issue 1 (2020)
- Year:
- 2020
- Volume:
- 7
- Issue:
- 1
- Issue Sort Value:
- 2020-0007-0001-0000
- Page Start:
- A36
- Page End:
- A36
- Publication Date:
- 2020-03-23
- Subjects:
- Systemic lupus erythematosus -- Periodicals
616.772005 - Journal URLs:
- http://www.bmj.com/archive ↗
http://lupus.bmj.com/ ↗ - DOI:
- 10.1136/lupus-2020-eurolupus.65 ↗
- Languages:
- English
- ISSNs:
- 2398-8851
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 19741.xml